摘要
目的探讨二甲双胍联合吡格列酮治疗2型糖尿病的临床疗效。方法入选的70例2型糖尿病患者,其中35例患者应用二甲双胍联合吡格列酮治疗,设为观察组,余35例2型糖尿病患者行二甲双胍治疗,设为对照组,应用统计学方法对比分析两组治疗6个月后的疗效及比较两组患者治疗前后空腹血糖(FBG)、餐后2h血糖(PBG)及糖化血红蛋白(HbA1C)的变化情况,同时注意并记录治疗过程中发生的不良反应情况。结果观察组治疗后的总有效率达94.3%,明显高于对照组治疗后的总有效率77.1%(P<0.05)。观察组与对照组患者治疗6个月后的FBG、2h PBG、HbA1C均较治疗前明显降低,且观察组患者的FBG、2h PBG、HbA1C均明显低于对照组(P<0.05)。结论二甲双胍联合吡格列酮治疗可以明显改善2型糖尿病的血糖和糖化血红蛋白水平,疗效确切,值得推广和应用。
Objective To investigate the clinical efficacy of metformin and pioglitazone in treatment of type 2 diabetes. Methods 70 cases type 2 diabetes, of which 35 patients were treated with metformin pioglitazone treatment, the establishment of the observation group, another 35 cases of type 2 diabetic patients were treated with metforminas as the control group, after treatment 6 months, fasting blood glucose （FBG）, 2h postprandial blood glucose （PBG） and glycosylated hemoglobin （HbA1C） changes and adverse reactions were compared between two groups. Results After treatment, the total effective rate of observation group was 94.3%, was significantly higher than the control group 77.1% （P 〈 0.05）. The FBG, 2h PBG, HbAIC of observation group and control group treated 6 months was significantly lower than before treatment, and the observation group was significantly lower than the control group, the difference was significant （P 〈 0.05）. Conclusion Metformin and pioglitazone can significantly improve blood sugar and glycosylated hemoglobin levels in type 2 diabetes, the efficacy is good, should be promoted and applied.
出处
《中国医药科学》
2013年第18期75-76,共2页
China Medicine And Pharmacy
